Khan Hannah, Aziz Aamir A, Sulahria Humza, Khan Huma, Ahmed Abrahim, Choudhry Netan, Narayanan Raja, Danzig Carl, Khanani Arshad M
University of Nevada, Reno School of Medicine, Reno, NV, USA.
Sierra Eye Associates, Reno, NV, USA.
Clin Ophthalmol. 2023 Jan 23;17:321-327. doi: 10.2147/OPTH.S367089. eCollection 2023.
Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD. Dry AMD can progress to a more advanced form that manifests as geographic atrophy (GA), which significantly threatens vision, leading to progressive and irreversible loss of visual function. There are currently no approved therapeutics commercially available for GA patients. However, data from various clinical trials have demonstrated favorable results with significant reduction in GA lesion growth. This review furthers the understanding of the pathophysiology of GA, as well as current clinical trial data on investigational therapeutics.
年龄相关性黄斑变性（AMD）是一种慢性多因素疾病，是不可逆失明的主要原因。晚期AMD分为新生血管性（湿性）AMD和非新生血管性（干性）AMD。干性AMD可进展为更晚期形式，表现为地图样萎缩（GA），这严重威胁视力，导致视觉功能进行性和不可逆丧失。目前尚无针对GA患者的获批商业治疗方法。然而，来自各种临床试验的数据显示了良好的结果，GA病变生长显著减少。本综述进一步加深了对GA病理生理学的理解，以及关于研究性治疗方法的当前临床试验数据。
